"Designing Growth Strategies is in our DNA"

Central Nervous System Treatment Market Size, Share, Trends & Industry Analysis, By Disease Type (Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, Infectious Diseases, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Others) By Drug Type (Biologics and Non-biologics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI103973

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Key Industry Developments- Mergers, Acquisitions and Partnerships
    2. New Product Launches
    3. Pipeline Analysis
    4. Overview of Regulatory Scenario
    5. Impact of COVID-19 on the Market
  5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S. (By Drug Type)
      2. Canada (By Drug Type)
  7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. U.K. (By Drug Type)
      2. Germany (By Drug Type)
      3. France (By Drug Type)
      4. Spain (By Drug Type)
      5. Italy (By Drug Type)
      6. Scandinavia (By Drug Type)
      7. Rest of Europe (By Drug Type)
  8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Japan (By Drug Type)
      2. China (By Drug Type)
      3. India (By Drug Type)
      4. Australia (By Drug Type)
      5. Southeast Asia (By Drug Type)
      6. Rest of Asia Pacific (By Drug Type)
  9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil (By Drug Type)
      2. Mexico (By Drug Type)
      3. Rest of Latin America (By Drug Type)
  10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. GCC Countries (By Drug Type)
      2. South Africa (By Drug Type)
      3. Rest of Middle East & Africa (By Drug Type)
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2024)
    3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
      1. Biogen
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Pfizer, Inc.
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. F. Hoffmann-La Roche Ltd
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      5. Johnson and Johnson Services Inc.
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      6. Teva Pharmaceutical Industries Lt
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      7. Sanofi
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      8. Otsuka Holdings
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      9. Other Prominent Players
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Key Industry Developments- Mergers, Acquisitions and Partnerships
    2. New Product Launches
    3. Pipeline Analysis
    4. Overview of Regulatory Scenario
    5. Impact of COVID-19 on the Market
  5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S. (By Drug Type)
      2. Canada (By Drug Type)
  7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. U.K. (By Drug Type)
      2. Germany (By Drug Type)
      3. France (By Drug Type)
      4. Spain (By Drug Type)
      5. Italy (By Drug Type)
      6. Scandinavia (By Drug Type)
      7. Rest of Europe (By Drug Type)
  8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Japan (By Drug Type)
      2. China (By Drug Type)
      3. India (By Drug Type)
      4. Australia (By Drug Type)
      5. Southeast Asia (By Drug Type)
      6. Rest of Asia Pacific (By Drug Type)
  9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. Brazil (By Drug Type)
      2. Mexico (By Drug Type)
      3. Rest of Latin America (By Drug Type)
  10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2024-2032
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulatory Drugs
      2. Interferons
      3. Decarboxylase Inhibitors
      4. Dopamine Agonists
      5. Antidepressants
      6. Analgesics
      7. Others
    3. Market Analysis, Insights and Forecast – By Disease Type
      1. Neurovascular Diseases
        1. Hemorrhagic Stroke
        2. Ischemic Stroke
        3. Others
      2. Neurodegenerative Diseases
        1. Alzheimer’s Disease
        2. Parkinson’s Disease
        3. Multiple Sclerosis
        4. Others
      3. Mental Health
        1. Epilepsy
        2. Mood Disorders
        3. Anxiety Disorders
        4. Others
        5. Infectious Diseases
        6. Meningitis
        7. Encephalitis
        8. Others
      4. Others
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Others
    5. Market Analysis, Insights and Forecast – By Drug Type
      1. Biologics
      2. Non-biologics
    6. Market Analysis, Insights and Forecast – By Country/ Sub-region
      1. GCC Countries (By Drug Type)
      2. South Africa (By Drug Type)
      3. Rest of Middle East & Africa (By Drug Type)
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2024)
    3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
      1. Biogen
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Pfizer, Inc.
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. F. Hoffmann-La Roche Ltd
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      5. Johnson and Johnson Services Inc.
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      6. Teva Pharmaceutical Industries Lt
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      7. Sanofi
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      8. Otsuka Holdings
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      9. Other Prominent Players
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
Read Less

Figure 1:  Global Central Nervous System Treatment Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032

Figure 2:  Global Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024 & 2032

Figure 3:  Global Central Nervous System Treatment Market Forecast (USD billion), by Multiple Sclerosis Drugs, 2024-2032

Figure 4:  Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-psychotic, 2024-2032

Figure 5:  Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-epileptic, 2024-2032

Figure 6:  Global Central Nervous System Treatment Market Forecast (USD billion), by Antidepressants, 2024-2032

Figure 7:  Global Central Nervous System Treatment Market Forecast (USD billion), by Psychostimulants, 2024-2032

Figure 8:  Global Central Nervous System Treatment Market Forecast (USD billion), by Narcotic Analgesics, 2024-2032

Figure 9:  Global Central Nervous System Treatment Market Forecast (USD billion), by Non-Narcotic Analgesics, 2024-2032

Figure 10:  Global Central Nervous System Treatment Market Forecast (USD billion), by Anaesthetics, 2024-2032

Figure 11:  Global Central Nervous System Treatment Market Forecast (USD billion), by Antiparkinsons, 2024-2032

Figure 12:  Global Central Nervous System Treatment Market Forecast (USD billion), by Sedatives, 2024-2032

Figure 13:  Global Central Nervous System Treatment Market Forecast (USD billion), by General Anaesthesia, 2024-2032

Figure 14:  Global Central Nervous System Treatment Market Forecast (USD billion), by Other CNS Products, 2024-2032

Figure 15:  Global Central Nervous System Treatment Market Value Share (%), by Drug Type, 2024 & 2032

Figure 16:  Global Central Nervous System Treatment Market Value Share (%), by Biologics, 2024 & 2032

Figure 17:  Global Central Nervous System Treatment Market Value Share (%), by Non-biologics, 2024 & 2032

Figure 18:  Global Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 19:  Global Central Nervous System Treatment Market Forecast (USD billion), by Hospital Pharmacy, 2024-2032

Figure 20:  Global Central Nervous System Treatment Market Forecast (USD billion), by Retail Pharmacy, 2024-2032

Figure 21:  Global Central Nervous System Treatment Market Forecast (USD billion), by Others, 2024-2032

Figure 22:  Global Central Nervous System Treatment Market Value (USD billion), by Region, 2024 & 2032

Figure 23:  North America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2024 & 2032

Figure 24:  North America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024

Figure 25:  North America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2024 & 2032

Figure 26:  North America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2024

Figure 27:  North America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 28:  North America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 29:  North America Central Nervous System Treatment Market Value (USD billion), By Country, 2024 & 2032

Figure 30:  North America Central Nervous System Treatment Market Value Share (%), By Country, 2024

Figure 31:  Europe Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2024 & 2032

Figure 32:  Europe Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024

Figure 33:  Europe Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2024 & 2032

Figure 34:  Europe Central Nervous System Treatment Market Value Share (%), By Drug Type, 2024

Figure 35:  Europe Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 36:  Europe Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 37:  Europe Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 38:  Europe Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 39:  Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2024 & 2032

Figure 40:  Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024

Figure 41:  Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2024 & 2032

Figure 42:  Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Type, 2024

Figure 43:  Asia Pacific Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 44:  Asia Pacific Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 45:  Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 46:  Asia Pacific Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 47:  Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2024 & 2032

Figure 48:  Latin America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024

Figure 49:  Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2024 & 2032

Figure 50:  Latin America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2024

Figure 51:  Latin America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 52:  Latin America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 53:  Latin America Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 54:  Latin America Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 55:  Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2024 & 2032

Figure 56:  Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Class, 2024

Figure 57:  Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2024 & 2032

Figure 58:  Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Type, 2024

Figure 59:  Middle East & Africa Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 60:  Middle East & Africa Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2024

Figure 61:  Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 62:  Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2024

Figure 63:  Global Central Nervous System Treatment Market Share (%), By Company, 2024

Table 1:  Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024–2032

Table 2:  Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024–2032

Table 3:  Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024–2032

Table 4:  Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Region, 2024-2032

Table 5:  North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024-2032

Table 6:  North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024-2032

Table 7:  North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024-2032

Table 8:  North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country, 2024-2032

Table 9:  Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024-2032

Table 10:  Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024-2032

Table 11: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024-2032

Table 12: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2024-2032

Table 13:  Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024-2032

Table 14: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024-2032

Table 15: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024-2032

Table 16: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2024-2032

Table 17:  Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024-2032

Table 18:  Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024-2032

Table 19:  Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024-2032

Table 20:  Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2024-2032

Table 21:  Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2024-2032

Table 22:  Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2024-2032

Table 23:  Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2024-2032

Table 24:  Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2024-2032

Central Nervous System Treatment Market
  • 2019-2032
  • 2024
  • 2019-2023
  • 160
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports